文献速递艾滋病与性传播感染

电灼、局部西多福韦与局部绿茶儿茶素治疗HIV感染者肛门高级别鳞状上皮内病变的疗效:开放标签随机对照试验

Effectiveness of Electrocautery, Topical Cidofovir, and Topical Sinecatechins for the Treatment of Anal High-Grade Squamous Intraepithelial Lesions in Persons With HIV: An Open-Label, Randomized Controlled Trial.
PubMed 文献 · Clin Infect Dis · 2025-01-01

TREATAIN试验在西班牙Vall d'Hebron医院将100名HIV感染者肛门HSIL按1:1:1随机分配至电灼组、局部1%西多福韦软膏组或局部10%绿茶儿茶素组。改良意向治疗分析显示组织学缓解率分别为69.4%、82.1%和61.1%,差异无统计学意义(P=0.189)。绿茶儿茶素组不良反应最少且满意度最高。

要点

  • 三种治疗HSIL的组织学缓解率无统计学显著差异(P=0.189)。
  • 绿茶儿茶素组不良反应报告率最低(33%),满意度最高(5.6±0.4)。
  • 48周随访期间三组复发率无显著差异(P=0.811)。

核心结论

  • 三种治疗间疗效未观察到统计学显著差异;绿茶儿茶素是最被接受且耐受性最好的治疗。

研究设计与样本

  • TREATAIN试验为开放标签随机对照研究,在西班牙Vall d'Hebron医院开展,HIV感染者肛门HSIL按1:1:1随机分配至电灼组、局部1%西多福韦软膏组或局部10%绿茶儿茶素组。
  • 2020年10月至2022年11月共入组100名参与者:电灼组36例、西多福韦组28例、绿茶儿茶素组36例。

主要发现

  • 改良意向治疗分析显示组织学缓解率:电灼组69.4%(95%CI 54.4%-84.5%)、西多福韦组82.1%(95%CI 67.9%-96.3%)、绿茶儿茶素组61.1%(95%CI 45.2%-77%),P=0.189。
  • 48周随访期间复发:电灼组7例(28%)、西多福韦组7例(30.4%)、绿茶儿茶素组8例(36.4%),log-rank检验P=0.811。
  • 副作用报告率:电灼组97.2%、西多福韦组85.7%、绿茶儿茶素组33%,P<0.001。
  • 满意度均值:绿茶儿茶素组5.6±0.4,电灼组5.1±0.8,西多福韦组4.77±0.96,P<0.001。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Doubts remain about the best treatment for managing premalignant lesions (high-grade squamous intraepithelial lesions [HSIL]) associated with anal cancer. METHODS: The TREATAIN trial was an open-label, randomized study conducted at Hospital Vall d'Hebron (Spain). Persons with human immunodeficiency virus and anal HSIL were randomly assigned 1:1:1 to receive treatment with electrocautery, topical cidofovir 1% ointment, or topical sinecatechins 10%. The primary outcome was histological resolution of HSIL. Secondary outcomes included adverse events, participant satisfaction, human papillomavirus clearance, and HSIL recurrence. RESULTS: Between October 2020 and November 2022, 100 participants were enrolled (36 in the electrocautery arm, 28 in the cidofovir arm, and 36 in the sinecatechins arm). Modified intention-to-treat analysis showed a response rate of 69.4% (95% confidence interval [CI]: 54.4%-84.5%) of patients in the electrocautery group, 82.1% (95% CI: 67.9%-96.3%) in the cidofovir group, and 61.1% (95% CI: 45.2%-77%) in the sinecatechins group (P = .189). During the 48-week follow-up period, recurrence was observed in 7 participants (28%) in the electrocautery group, 7 (30.4%) in the cidofovir group, and 8 (36.4%) in the sinecatechins group (log-rank test, P = .811). Side effects were reported by 97.2% of patients in the electrocautery group, 85.7% in the cidofovir group, and 33% in the sinecatechins group (P < .001). Patients were more satisfied with the sinecatechins treatment (mean, 5.6 ± 0.4), followed by electrocautery (mean, 5.1 ± 0.8), while lower satisfaction was reported with cidofovir treatment (mean, 4.77 ± 0.96) (P < .001). CONCLUSIONS: No statistically significant difference was observed in efficacy between treatments; in contrast, sinecatechins was the most accepted and well-tolerated treatment. Clinical Trials Registration. EudraCT: 2018-001730-18; ClinicalTrials.gov: NCT04055142.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Burgos J, Curran A, Garcia J, et al. Effectiveness of Electrocautery, Topical Cidofovir, and Topical Sinecatechins for the Treatment of Anal High-Grade Squamous Intraepithelial Lesions in Persons With HIV: An Open-Label, Randomized Controlled Trial. Clin Infect Dis. 2025. PMID: 40036375. doi:10.1093/cid/ciaf086

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。